https://www.selleckchem.com/pr....oducts/cremophor-el.
001), vena contracta -0.11 cm (95% CI -0.20 to -0.02; P 0.05), and effective regurgitant orifice area -0.03 cm (95% CI -0.06 to -0.01; P 0.05). There were non-significant improvements in LV ejection fraction and volumes. Survival over 1year was 89% with no difference between mild (96%) and moderate (86%) SMR (log-rank P= 0.22). Progression-free survival was 70% (82% in mild vs. 63% in moderate SMR; P= 0.16). Freedom from HF hospitalization was 73% (87% in mild SMR vs. 66% in moderate SMR; P= 0.07). Among patients with sympt
Beğen
Yorum Yap
Paylaş
